Albert S. Chiou

2 weeks ago | dermatologytimes.com | Albert S. Chiou |Kaitlyn Bader

“This is the first time that a selective ITK inhibitor has been studied in atopic dermatitis or any human immune-mediated disease for that matter. I think this trial is a real step forward in giving us a potential new way to selectively target TH2 and TH17 with an oral medication with an acceptable safety profile,” said Albert Chiou, MD, MBA, in an interview with Dermatology Times.